EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISM® in Schizophrenia

Marco Solmi, Olivier Corbeil iD, Maïa Miguelez iD, Ric M Procyshyn iD, Pierre Blier, Maxime Barakat, Christoph U Correll iD

Journal of Clinical Medicine · 18.08.2026 · 15 (16) · 6393

DOI: 10.3390/jcm15166393 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.08.2026. Verfasst von Marco Solmi und 6 weiteren Autor:innen. Beteiligte Einrichtung: SCIENCES Lab, Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bausch Health, Canada, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonadherence to medications for psychosis is a major challenge in the management of schizophrenia and is associated with an increased risk of relapse, hospitalization, functional deterioration, and premature death. Although long-acting injectable (LAI) medications for psychosis improve treatment continuity, important differences exist among LAIs regarding initiation regimen, attainment of therapeutic blood level exposure, and steady state, dosing, and switching. Risperidone ISM® is an intramuscular LAI administered every four weeks, designed to provide rapid and sustained therapeutic exposure without the need for loading doses or oral supplementation. This narrative review translates the pharmacokinetic (PK) and pharmacodynamic (PD) profile of risperidone ISM® into expert-informed guidance for treatment initiation, dose optimization, switching, and ongoing schizophrenia management. Risperidone ISM® achieves therapeutic exposure within hours of administration and maintains plasma concentrations and dopamine D2 receptor occupancy at levels associated with antipsychotic efficacy throughout the dosing interval, supporting continuous antipsychotic coverage and stability. Its PK profile, as characterized in clinical studies, and simplified initiation regimen may facilitate clinical decision-making across treatment settings, including transitions from oral risperidone or other medications for psychosis and continuity of care following hospitalization or relapse, while supporting symptom stability, functioning, and patient engagement. By translating PK/PD characteristics into practical clinical implications, this review aims to support clinicians in optimizing the use of risperidone ISM® as part of individualized, recovery-oriented care in the short- and long-term management of people living with schizophrenia across settings. The recommendations presented reflect expert interpretation of the available PK/PD, clinical trial, observational, and product-label evidence, supplemented by clinical experience.

Schlagwörter

Stichwörter der Autor:innen

acute exacerbationadherenceantipsychotic switchingdopamine D2 receptor occupancyefficacylong-acting injectable antipsychoticspharmacodynamicspharmacokineticsrisperidone ISMsafetyschizophreniatolerability

Autor:innen und Institutionen

  • SCIENCES Lab, Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
  • Department of Mental Health, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada.
  • Ottawa Hospital Research Institute (OHRI), Ottawa, ON K1H 8L6, Canada.
  • Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité Universitätsmedizin-Berlin, 10117 Berlin, Germany.
  • Department of Pharmacy, Institut Universitaire en Santé Mentale de Québec, Quebec, QC G1J 2G3, Canada.
  • Faculty of Pharmacy, Université Laval, Quebec, QC G1V 0A6, Canada.

ORCID-Profile: Olivier Corbeil, Maïa Miguelez, Ric M Procyshyn, Christoph U Correll

Förderung

  • Bausch Health, Canada, Inc.

Zitieren

APA

Solmi, M., Corbeil, O., Miguelez, M., Procyshyn, R. M., Blier, P., Barakat, M., & Correll, C. U. (2026). Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISM® in Schizophrenia. Journal of Clinical Medicine, 15(16), 6393. https://doi.org/10.3390/jcm15166393

Vancouver

Solmi M, Corbeil O, Miguelez M, Procyshyn RM, Blier P, Barakat M, et al. Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISM® in Schizophrenia. Journal of Clinical Medicine. 2026;15(16):6393. doi:10.3390/jcm15166393

BibTeX
@article{Solmi2026,
  author = {Solmi, Marco and Corbeil, Olivier and Miguelez, Maïa and Procyshyn, Ric M and Blier, Pierre and Barakat, Maxime and Correll, Christoph U},
  title = {Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISM® in Schizophrenia},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {6393},
  doi = {10.3390/jcm15166393}
}
Kostenlos starten →